It was predicted that Omomyc had the potential to disrupt the Myc/Max/Mxd network and act as an inhibitor of c-Myc function [99], and it has been shown to induce tumor regression in multiple cancer models, including pancreatic, lung, breast and brain cancer through a range of effects including reduced cell proliferation and increased apoptosis [43–45, 49, 100–104, 149]. This evidence concerns the gene MYC and brain cancer.